Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

  title={Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.},
  author={M. Sanda and D. Smith and L. Charles and C. Hwang and K. Pienta and J. Schlom and D. Mileni{\'c} and D. Panicali and J. Montie},
  volume={53 2},
  • M. Sanda, D. Smith, +6 authors J. Montie
  • Published 1999
  • Medicine
  • Urology
  • OBJECTIVES Prostate cancer recurrence, evidenced by rising prostate-specific antigen (PSA) levels after radical prostatectomy, is an increasingly prevalent clinical problem in need of new treatment options. Preclinical studies have suggested that for tumors in general, settings of minimal cancer volume may be uniquely suitable for recombinant vaccine therapy targeting tumor-associated antigens. A clinical study was undertaken to evaluate the safety and biologic effects of vaccinia-PSA (PROSTVAC… CONTINUE READING
    200 Citations
    Prostate-specific antigen vaccines for prostate cancer
    • 17
    Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
    • H. Kaufman, W. Wang, +7 authors L. Weiner
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 237
    Advances in Prostate Cancer Immunotherapies
    • 18
    • PDF
    Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results
    • 80
    • PDF
    A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
    • J. Eder, P. Kantoff, +11 authors D. Kufe
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2000
    • 300
    • PDF


    Adjuvant immunotherapy (BCG) in stage D prostate cancer.
    • 25
    Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
    • 172
    • PDF